CL2014000927A1 - Proteinas naglu humana recombinante y usos de la misma - Google Patents

Proteinas naglu humana recombinante y usos de la misma

Info

Publication number
CL2014000927A1
CL2014000927A1 CL2014000927A CL2014000927A CL2014000927A1 CL 2014000927 A1 CL2014000927 A1 CL 2014000927A1 CL 2014000927 A CL2014000927 A CL 2014000927A CL 2014000927 A CL2014000927 A CL 2014000927A CL 2014000927 A1 CL2014000927 A1 CL 2014000927A1
Authority
CL
Chile
Prior art keywords
recombinant human
human naglu
naglu proteins
proteins
recombinant
Prior art date
Application number
CL2014000927A
Other languages
English (en)
Spanish (es)
Inventor
Anthony Quinn
Markley C Leavitt
Xia Zhinan
Joseph Victor Rutkowski
Original Assignee
Synageva Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synageva Biopharma Corp filed Critical Synageva Biopharma Corp
Publication of CL2014000927A1 publication Critical patent/CL2014000927A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
CL2014000927A 2011-10-12 2014-04-11 Proteinas naglu humana recombinante y usos de la misma CL2014000927A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161546248P 2011-10-12 2011-10-12

Publications (1)

Publication Number Publication Date
CL2014000927A1 true CL2014000927A1 (es) 2014-11-14

Family

ID=48082738

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014000927A CL2014000927A1 (es) 2011-10-12 2014-04-11 Proteinas naglu humana recombinante y usos de la misma

Country Status (18)

Country Link
US (3) US20140255383A1 (enExample)
EP (1) EP2766477B1 (enExample)
JP (1) JP6329483B2 (enExample)
KR (1) KR20140108519A (enExample)
CN (1) CN103958676A (enExample)
AU (1) AU2012322811A1 (enExample)
BR (1) BR112014008873A2 (enExample)
CA (1) CA2852027A1 (enExample)
CL (1) CL2014000927A1 (enExample)
CO (1) CO7010783A2 (enExample)
HK (1) HK1200489A1 (enExample)
IL (1) IL232073A0 (enExample)
IN (1) IN2014MN00740A (enExample)
MX (1) MX2014004359A (enExample)
RU (1) RU2014117291A (enExample)
SG (2) SG10201510106PA (enExample)
TW (1) TW201321515A (enExample)
WO (1) WO2013055888A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022349A2 (en) 2006-08-18 2008-02-21 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
CA2694762A1 (en) 2007-07-27 2009-02-05 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
HUE044865T2 (hu) 2009-10-09 2019-11-28 Armagen Inc Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
RU2550961C2 (ru) 2010-09-09 2015-05-20 Синаджева Биофарма Корп. Использование кислой лизосомной липазы для лечения дефицита кислой лизосомной липазы у больных
KR20140006037A (ko) 2011-02-15 2014-01-15 시나게바 바이오파르마, 코포레이션 리소좀의 산 리파제 결핍을 치료하는 방법들
JP6329483B2 (ja) * 2011-10-12 2018-05-23 シナジェバ・バイオファーマ・コーポレイションＳｙｎａｇｅｖａ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐ． 組換えヒトｎａｇｌｕタンパク質およびその利用
ES2983576T3 (es) 2011-12-02 2024-10-23 Armagen Inc Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC
RU2692251C2 (ru) 2013-05-15 2019-06-24 Риджентс Оф Зэ Юниверсити Оф Миннесота Опосредованный аденоассоциированным вирусом перенос генов в центральную нервную систему
TW202332774A (zh) * 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
MX383227B (es) * 2014-05-14 2025-03-13 UNIV AUTòNOMA DE BARCELONA Vectores de virus adenoasociados para el tratamiento de trastornos de almacenamiento lisosomico.
WO2015200675A1 (en) * 2014-06-25 2015-12-30 Shire Human Genetic Therapies, Inc. Generation of mannose-6-phosphate containing recombinant alpha-n-acetyl glucosaminidase
AU2015301809A1 (en) * 2014-08-11 2017-02-02 Shire Human Genetic Therapies, Inc. Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
AU2015323966A1 (en) * 2014-09-29 2017-03-16 Alexion Pharmaceuticals, Inc. Methods of treating mucopolysaccharidosis IIIB (MPSIIIB)
CN104524662B (zh) * 2014-12-31 2017-02-22 迈得医疗工业设备股份有限公司 一种医用针座组装的上料机构
US10538589B2 (en) * 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
WO2017132675A1 (en) * 2016-01-29 2017-08-03 Alexion Pharmaceuticals, Inc. Enzyme replacement therapy in mucopolysaccharidosis iiib patients
WO2017181113A1 (en) 2016-04-15 2017-10-19 The Trustees Of The University Of Pennsyvania Gene therapy for treating mucopolysaccharidosis type ii
US10633705B2 (en) * 2016-10-14 2020-04-28 Alexion Pharmaceuticals, Inc. N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods
TWI835747B (zh) 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
CA3169548A1 (en) * 2020-03-23 2021-09-30 Haiyan Fu Aav-naglu vectors for treatment of mucopolysaccharidosis iiib
CN111718947B (zh) * 2020-06-18 2022-08-23 舒泰神（北京）生物制药股份有限公司 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825396B2 (en) 1996-06-12 2004-11-30 Board Of Trustees Operating Michigan State University Methods for tissue specific synthesis of protein in eggs of transgenic hens
US5897998A (en) 1997-08-04 1999-04-27 The University Of Georgia Research Foundation, Inc. Method for manipulating avian eggs
US20040019923A1 (en) 1997-10-16 2004-01-29 Ivarie Robert D. Exogenous proteins expressed in avians and their eggs
US7511120B2 (en) 1997-10-16 2009-03-31 Synageva Biopharma Corp. Glycosylated G-CSF obtained from a transgenic chicken
JP2001520009A (ja) 1997-10-16 2001-10-30 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド 鳥の導入遺伝子についてのマグナム特異的プロモーターを含むベクター
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US7138262B1 (en) * 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US6679165B2 (en) 2002-05-22 2004-01-20 Shiny Shih Window adapted to a dater
US20050142141A1 (en) 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US20040248262A1 (en) 2003-01-22 2004-12-09 Koeberl Dwight D. Constructs for expressing lysomal polypeptides
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050090001A1 (en) 2003-10-07 2005-04-28 Parker Stephen H. Cell lines and methods for producing proteins
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
EP1746902A4 (en) * 2004-05-05 2007-06-13 Univ Northeastern MULTI-LECTIN AFFINITY CHROMATOGRAPHY AND USES THEREOF
CA2641070C (en) * 2006-02-06 2017-01-03 Ramot At Tel-Aviv University Ltd. Enzyme replacement therapy for treating lysosomal storage diseases
CN101410408A (zh) 2006-04-04 2009-04-15 希尔制药爱尔兰有限责任公司 用于浓缩多肽的方法
EP2126071A4 (en) 2007-01-26 2010-12-08 Synageva Biopharma Corp TRANSGENEXPRESSION IN BIRDS
US8431770B2 (en) * 2008-01-07 2013-04-30 Synageva Biopharma Corp. Method of producing sialytransferase-modified proteins
WO2009131698A2 (en) 2008-04-23 2009-10-29 Iowa State University Research Foundation, Inc. PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF
CA2766614C (en) * 2009-07-03 2018-06-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
US20110318327A1 (en) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
DK2588130T3 (en) * 2010-06-25 2016-10-24 Shire Human Genetic Therapies Cns delivery of therapeutic agents
EP2975134A3 (en) * 2010-07-22 2016-02-24 Shire Human Genetic Therapies, Inc. Crystal structure of human alpha-n-acetylglucosaminidase
RU2550961C2 (ru) 2010-09-09 2015-05-20 Синаджева Биофарма Корп. Использование кислой лизосомной липазы для лечения дефицита кислой лизосомной липазы у больных
JP6329483B2 (ja) * 2011-10-12 2018-05-23 シナジェバ・バイオファーマ・コーポレイションＳｙｎａｇｅｖａ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐ． 組換えヒトｎａｇｌｕタンパク質およびその利用

Also Published As

Publication number Publication date
RU2014117291A (ru) 2015-11-20
AU2012322811A1 (en) 2014-05-01
NZ623690A (en) 2016-08-26
US20140255383A1 (en) 2014-09-11
KR20140108519A (ko) 2014-09-11
US20170216412A1 (en) 2017-08-03
BR112014008873A2 (pt) 2020-09-15
CN103958676A (zh) 2014-07-30
EP2766477A4 (en) 2015-07-15
SG11201401457SA (en) 2014-05-29
MX2014004359A (es) 2014-05-28
WO2013055888A2 (en) 2013-04-18
HK1200489A1 (en) 2015-08-07
CA2852027A1 (en) 2013-04-18
JP2014534962A (ja) 2014-12-25
CO7010783A2 (es) 2014-07-31
IL232073A0 (en) 2014-05-28
TW201321515A (zh) 2013-06-01
IN2014MN00740A (enExample) 2015-05-22
EP2766477B1 (en) 2018-09-26
JP6329483B2 (ja) 2018-05-23
US20130095092A1 (en) 2013-04-18
EP2766477A2 (en) 2014-08-20
SG10201510106PA (en) 2016-01-28
WO2013055888A3 (en) 2013-06-13
US9579366B2 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
CL2014000927A1 (es) Proteinas naglu humana recombinante y usos de la misma
BR112014000055A2 (pt) polipeptídeos de fusão de relaxina e usos dos mesmos
CL2014003605A1 (es) Proteínas de fusión de interleuquina-10 y usos de las mismas
HRP20181447T1 (hr) Pripravci glp-1 peptida i njihova priprava
BR112013023743A2 (pt) anticorpo de fator de tecidos humanos e usos do mesmo
BR112015003838A2 (pt) formulações de anticorpo e proteína
CO7020851A2 (es) Proteínas y péptidos modificados
IL279676A (en) Recombinant proteins and therapeutic uses
EP2929045A4 (en) PROTEIN EXPRESSION REINFORCING POLYPEPTIDES
BR112015011111A2 (pt) proteína multifuncional e formulação farmacêutica
DK2970398T3 (da) Præfusions-rsv-f-proteiner og anvendelse deraf
ME03075B (me) Prolaktin receptor vezujući proteini i njihova upotreba
BR112013029932A2 (pt) composições anti-cgrp e usos das mesmas
CO7020878A2 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CO7081145A2 (es) Uso terapéutico de la proteína de unión a neurotrofina p75ntr
EP2905290A4 (en) HETERODIMER PROTEIN COMPOSITION
CL2015000097A1 (es) Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos.
BR112014019459A2 (pt) proteínas de ligação à cdim e usos das mesmas
DK3415525T3 (da) Amfipatisk peptid
DK3321287T3 (da) Fusionsproteiner og kombinationsvacciner
EP2547771A4 (en) PREPARATION OF PROTEINS AND POLYPEPTIDES
HUE045845T2 (hu) Módosított relaxin polipeptidek és felhasználásuk
IL229723A0 (en) Human fusion proteins including interferons and modified targeted ubiquitin proteins
BR112014004936A2 (pt) polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo
PL2928905T3 (pl) Sposób oczyszczania białek terapeutycznych